Treatment rationale and design of the SPIRAL study: A phase II trial of osimertinib in elderly epidermal growth factor receptor T790M-positive nonsmall-cell lung cancer patients who progressed during prior EGFR-TKI treatment

• Published in: Medicine (Baltimore) Vol. 97; no. 23; p. e11081
• Main Authors: Uchino, Junji, Nakao, Akira, Tamiya, Nobuyo, Kaneko, Yoshiko, Yamada, Tadaaki, Yoshimura, Kenichi, Fujita, Masaki, Takayama, Koichi
• Format: Journal Article
• Language: English
• Published: United States The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved 01.06.2018; Wolters Kluwer Health
• Subjects: Acrylamides; Aged; Aged, 80 and over; Aniline Compounds; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm - genetics; ErbB Receptors - drug effects; ErbB Receptors - genetics; Female; Genes, erbB-1 - genetics; Humans; Lung Neoplasms - pathology; Male; Mutation - drug effects; Mutation - genetics; Neoplasm Staging; Piperazines - administration & dosage; Piperazines - pharmacology; Prospective Studies; Protein Kinase Inhibitors - pharmacology; Study Protocol Clinical Trial

Advances in epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment led to research on the mechanism of the resistance have revealed that an occurrence of T790M gene mutation generated in exon 20 of the EGFR gene is associated with approximately 50% to 60% of observed resista...